Can Massachusetts Employees Be Fired for a Positive THC Drug Test with a Medical Card? (2026 Doctor's Guide)
Quick Answer: Can You Be Fired in Massachusetts for a Positive THC Test with a Med Card?
Under the Massachusetts Supreme Judicial Court ruling in Barbuto v. Advantage Sales & Marketing LLC (2017), off-duty medical cannabis use is protected under the state handicap discrimination statute (M.G.L. c. 151B). Employers cannot terminate a certified patient solely for testing positive for THC without engaging in an interactive dialogue to determine reasonable accommodation, unless the job is subject to federal drug-free mandates.
| Benefit / Legal Protection | Massachusetts Medical Patient | Adult-Use (Recreational) Consumer |
|---|---|---|
| Dispensary Retail Taxes | 0% Total Tax (100% Tax-Free) | 20% Surcharge (Excise + Sales + Local) |
| Possession / Purchase Limit | 10 Ounces Every 60 Days | 1 Ounce Flower / 5g Concentrate / Day |
| Edibles Dosing Limit | No Milligram Cap (Clinical Potencies) | Max 5mg / Serving (100mg / Package) |
| Age Qualification | Ages 18+ Qualify Independently | Strictly 21+ Required |
Massachusetts state law, anchored by the landmark Barbuto v. Advantage Sales & Marketing ruling and M.G.L. c. 151B, generally prohibits employers from terminating registered medical cannabis patients solely for a positive THC drug test—but critical exceptions exist for federally regulated roles, safety-sensitive positions, and federal contractors. In 2026, with cannabis still federally classified as a Schedule I substance pending full DEA rescheduling, the gap between state protections and federal obligations remains the single most dangerous blind spot for Massachusetts patients.
| Audience | Massachusetts Medical Cannabis Patients, Employees, HR Professionals & Clinicians |
| Primary Topic | Employment Rights for Medical Cannabis Patients in Massachusetts After a Positive THC Drug Test |
| Legal Authority | Massachusetts Cannabis Control Commission Regulations (935 CMR 501) |
Can Massachusetts Employees Be Fired for a Positive THC Drug Test with a Medical Card? (2026 Doctor's Guide)
A positive THC drug test can feel like a career-ending event—but for registered Massachusetts medical cannabis patients, state law provides meaningful, though not absolute, workplace protections. Understanding exactly where those protections begin and end is not a legal technicality; it is a clinical necessity your certifying physician should walk you through before you ever visit a dispensary.
- How M.G.L. c. 151B and the Barbuto precedent create state-level employment protections for registered medical cannabis patients in Massachusetts
- Which employment categories—federal contractors, DOT-regulated drivers, safety-sensitive roles—remain fully outside state protection regardless of medical card status
- Why THC's prolonged metabolite window (up to 30 days in urine) creates a unique drug-testing problem that differs fundamentally from alcohol or opioid impairment testing
- How maintaining a valid MassCIP registration, physician documentation, and a clear treatment record strengthens a patient's legal position if challenged by an employer
- Practical steps Massachusetts patients should take before starting cannabis therapy to assess their specific workplace risk and document their medical necessity
- Massachusetts state law generally protects registered medical cannabis patients from termination solely for a positive THC test—but not universally
- The Barbuto ruling under M.G.L. c. 151B requires employers to consider reasonable accommodation before firing a medical patient
- Federal contractors, DOT-regulated workers, and safety-sensitive employees remain unprotected by state law regardless of their medical card
- Patients should document their certification, discuss workplace risk with their certifying physician, and never assume a medical card is a blanket shield
| Target Question | Can Massachusetts Employees Be Fired for a Positive THC Drug Test with a Medical Card? |
| Massachusetts Legal Basis | M.G.L. c. 151B (anti-discrimination), M.G.L. c. 94I (medical cannabis), Barbuto v. Advantage Sales & Marketing (2017 SJC ruling) |
| Qualifying Standard | Valid MassCIP registration as a certified medical cannabis patient under 935 CMR 501.000 |
| Key Limitation | Federal contractors, DOT-regulated employees, and safety-sensitive roles are exempt from state protections |
| THC Detection Window | Urine metabolites detectable up to 30 days; does not indicate current impairment |
| Possession Limit | 60-day rolling supply of up to 10 ounces of cannabis flower or equivalent for registered patients |
| Certification Method | Physician clinical evaluation followed by immediate online MassCIP portal registration and temporary digital certificate |
For the roughly 100,000 active registered medical cannabis patients in Massachusetts, a positive workplace drug test is not a hypothetical risk—it is a lived reality that can trigger termination, loss of professional licensure, or disqualification from federal employment. Unlike alcohol, which clears the body within hours, THC metabolites can remain detectable in urine for up to 30 days after last use, meaning a patient who consumed cannabis legally on a Friday evening may test positive the following Monday morning with zero functional impairment. The mismatch between detection windows and actual impairment is a core clinical injustice that patients deserve to understand before they begin therapy. The legal landscape in Massachusetts is more protective than most states, but it is not a blanket shield. Employers, HR departments, and even some employment attorneys routinely misstate the scope of Barbuto protections—either overstating them to avoid accommodation conversations or understating them to justify termination. As a certifying physician, I consider it part of my clinical duty to ensure every patient I certify understands their specific workplace risk profile before they fill their first prescription at a dispensary. The stakes are simply too high for ambiguity.
Massachusetts offers some of the strongest state-level employment protections for medical cannabis patients in the country, but those protections are conditional, not absolute. The Barbuto decision established that disability discrimination law can apply when an employer refuses to accommodate a registered patient's off-duty cannabis use—but it did not create an unconditional right to test positive and keep your job. The nature of your employer, your role, and whether federal law governs your workplace determines everything. My clinical advice is consistent: before you begin cannabis therapy, have an honest conversation with your certifying physician about your specific employment context. Bring your job description. Mention if your employer holds federal contracts, if you operate heavy machinery, or if you hold a commercial driver's license. A medical card is a powerful legal and therapeutic tool—but like any tool, it works best when you understand exactly what it can and cannot do.
The foundational legal protection for Massachusetts medical cannabis patients in the workplace comes not from cannabis law itself, but from disability discrimination law. In 2017, the Massachusetts Supreme Judicial Court ruled in Barbuto v. Advantage Sales & Marketing that an employer's termination of a registered medical cannabis patient solely because of a positive drug test could constitute handicap discrimination under M.G.L. c. 151B. The court held that employers must engage in an interactive process to determine whether reasonable accommodation is possible before terminating a patient—the same standard applied to any other disability-related medication or treatment.
Critically, M.G.L. c. 94I—the statute governing the medical cannabis program administered by the Cannabis Control Commission under 935 CMR 501.000—does not itself mandate employer accommodation. The Barbuto protection flows through disability law, which means it applies only when the patient's underlying condition qualifies as a handicap under state law. Anxiety disorders, PTSD, chronic pain, and other debilitating conditions that commonly qualify for cannabis certification also typically qualify as protected disabilities—creating a meaningful, if imperfect, legal shield.
What the law does not do is prohibit employers from maintaining drug-free workplace policies, testing for THC, or terminating employees who test positive when federal law or legitimate safety concerns require it. The accommodation obligation has limits: employers are not required to permit impairment on the job, and they are not required to violate federal law to accommodate a state-law patient. In 2026, with cannabis still pending full federal rescheduling, this federal-state tension remains the central fault line in Massachusetts employment cannabis law.
Federal contractors and subcontractors operating under the Drug-Free Workplace Act of 1988 are required to maintain drug-free workplace policies as a condition of federal funding. For employees in these workplaces, a Massachusetts medical card provides no protection whatsoever—federal law preempts state accommodation obligations, and a positive THC test can lawfully result in termination regardless of your registration status or the legitimacy of your medical need.
Employees regulated by the U.S. Department of Transportation—including commercial truck drivers (CDL holders), airline pilots, railroad workers, transit operators, and maritime workers—are subject to federal DOT drug testing regulations that explicitly prohibit cannabis use. The Federal Motor Carrier Safety Administration has made clear that a state medical cannabis card is not a valid medical explanation for a positive DOT drug test. This is one of the most common and devastating misunderstandings I encounter in clinical practice: a patient with a valid Massachusetts medical card who holds a CDL can lose their commercial driving privileges permanently after a single positive test.
Safety-sensitive positions—even outside formal federal regulation—may also fall outside Barbuto's reach. Courts have consistently held that employers need not accommodate cannabis use when the employee's role involves operating heavy machinery, working at heights, handling firearms, or performing tasks where impairment creates direct risk of serious injury. The key legal question is whether the accommodation poses an undue hardship or a direct threat to workplace safety—and in safety-sensitive contexts, courts have generally sided with employers.
THC's psychoactive effects typically last two to six hours depending on route of administration, dose, and individual metabolism. But standard urine immunoassay drug tests do not detect THC itself—they detect THC-COOH, an inactive metabolite produced as the liver processes cannabinoids. This metabolite accumulates in fatty tissue and is released slowly over days to weeks, meaning a daily cannabis patient may test positive for 20 to 30 days after their last use with no residual functional impairment whatsoever. Occasional users typically clear within three to seven days.
This detection-impairment mismatch is not a technicality—it is a fundamental scientific problem with how workplace drug testing is currently designed. Breathalyzer technology for THC remains unreliable and is not yet validated for workplace use in 2026, despite ongoing research. Blood THC levels correlate more closely with recent use but are invasive and rarely used in routine employment screening. Until impairment-based testing replaces metabolite-based testing, registered medical patients will continue to face termination risk for off-duty, legal, medically supervised cannabis use that occurred days before any workplace interaction.
The single most important protective step a Massachusetts medical cannabis patient can take is proactive documentation before any workplace drug test occurs. This means maintaining a current MassCIP registration, keeping your physician certification up to date, and having a clear written record of your qualifying condition, treatment rationale, and the physician who certified you. If you are ever challenged by an employer, this documentation forms the evidentiary foundation of any accommodation request or discrimination claim.
Disclosure is a deeply personal and strategically complex decision. Massachusetts law does not require you to disclose your medical cannabis use or card status to your employer proactively—and in many workplace cultures, voluntary disclosure before a positive test may trigger adverse consequences without providing legal benefit. However, if you work in a role where you believe a drug test is likely, consulting with both your certifying physician and an employment attorney before disclosure is strongly advisable. The interactive accommodation process under Barbuto works best when initiated promptly and in writing after a positive test, not after termination has already occurred.
Review your employee handbook, any federal contract disclosures your employer has signed, and your job description for safety-sensitive language before beginning cannabis therapy. These documents will tell you more about your actual legal risk than any general summary of Massachusetts law. Bring them to your clinical consultation.
As of 2026, the DEA's proposed rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act remains in process, with final rule publication still pending. Schedule III rescheduling would not legalize cannabis federally or automatically eliminate Drug-Free Workplace Act obligations—but it would meaningfully reduce the federal legal basis for treating cannabis as categorically equivalent to heroin in employment contexts. Employers and federal agencies would need to revisit their drug testing policies, and the legal landscape for accommodation claims could shift substantially.
For Massachusetts patients right now, the practical implication is this: do not assume rescheduling has already changed your workplace rights. Until a final federal rule is published and employer policies are updated, the current framework—state protections with significant federal carve-outs—remains operative. Monitor updates from the Cannabis Control Commission and consult your physician annually to ensure your certification and understanding of the law remain current.
The employment protection framework for Massachusetts medical cannabis patients rests on a solid foundation of state appellate law—the Barbuto SJC ruling is binding precedent, not merely persuasive authority—combined with the well-established disability accommodation framework under M.G.L. c. 151B. The scientific evidence on THC's detection-impairment mismatch is robust and uncontested in the pharmacological literature: multiple peer-reviewed studies confirm that urine THC-COOH detection windows bear no reliable relationship to functional impairment. Where the evidence base is weaker is in predicting how individual employers, HR departments, and lower courts will apply Barbuto's interactive process requirement in specific factual contexts—the case law is still developing, and outcomes vary considerably based on the nature of the role, the employer's industry, and the quality of the patient's documentation.
Legitimate skepticism is warranted about the practical enforceability of Barbuto protections for workers without the financial resources to pursue employment discrimination litigation. The accommodation process requires an employer to engage in good faith—but enforcement depends on the patient filing a complaint with the Massachusetts Commission Against Discrimination (MCAD) or pursuing civil litigation, both of which are time-consuming, expensive, and emotionally draining. Patients in at-will employment relationships, gig economy roles, or small businesses with fewer than six employees may find that their theoretical legal rights provide little practical protection. Additionally, some cannabis industry marketing materials overstate the breadth of Massachusetts employment protections in ways that can give patients false confidence—always verify your specific situation with a licensed Massachusetts employment attorney, not a dispensary budtender.
A Massachusetts medical cannabis card does not make you immune to workplace drug testing, does not prohibit employers from having drug-free workplace policies, and does not override federal law in any federally regulated employment context. It does not mean you can consume cannabis before or during work hours and claim protection—no court has held that employers must tolerate on-the-job impairment. It does not protect your commercial driver's license, your federal security clearance, or your eligibility for federally funded housing or benefits. And it does not eliminate the need for a thoughtful, individualized conversation with both your certifying physician and, where appropriate, an employment attorney before you begin therapy.
The collision between state cannabis legalization and federal employment law is not unique to Massachusetts—it is a national policy crisis playing out in every state with a medical or adult-use cannabis program. What makes Massachusetts distinctive is the Barbuto precedent, which places the Commonwealth among a small group of states where disability law has been successfully invoked to protect medical patients from termination. States like Texas, Georgia, and Florida offer no comparable protection, leaving patients in those jurisdictions entirely at their employer's discretion regardless of their medical need.
The broader clinical reality is that many patients who use cannabis medicinally are managing conditions—chronic pain, PTSD, anxiety, multiple sclerosis—that already create workplace challenges. The fear of a positive drug test can itself become a source of significant anxiety, leading some patients to under-dose, use less effective delivery methods, or abandon therapy altogether to preserve their employment. This therapeutic compromise is a direct consequence of policy failure, and it is something I see regularly in clinical practice. Patients deserve a system where their medical treatment does not force them to choose between their health and their livelihood.
Integrating cannabis therapy into a patient's broader treatment plan requires attention to the full context of their life—including their employment. A comprehensive clinical consultation should address not just dosing and chemovar selection, but also the patient's workplace environment, drug testing policies, and the specific legal protections available to them. Cannabis medicine practiced responsibly is whole-person medicine, and employment risk is as much a part of that picture as drug interactions or sleep quality.
I have certified thousands of Massachusetts patients for medical cannabis, and the question I hear more than almost any other is some version of: 'Will I lose my job?' It is the right question to ask, and I am glad patients ask it before they begin therapy rather than after a positive test. My honest answer is always the same: it depends—on your employer, your role, your industry, and whether federal law governs your workplace. The Barbuto decision is real and meaningful protection, but it is not a magic shield, and I would be doing my patients a disservice if I told them otherwise.
What I have learned from years of navigating this with patients is that documentation and proactive planning are the most powerful tools available. Patients who come to me with their employee handbook, who know whether their employer holds federal contracts, and who have thought carefully about their specific role are in a fundamentally stronger position than those who assume a medical card automatically protects them. Part of what I do at CED Clinic is help patients build that clinical and documentary record—not just for dispensary access, but for the real-world legal situations they may face.
I also want to say something that does not get said enough: the fact that a patient can be fired for using a legally prescribed, medically supervised treatment for a legitimate debilitating condition—while a colleague who drinks alcohol every evening faces no comparable workplace scrutiny—is a profound injustice. The detection-impairment mismatch in THC testing is not a technicality; it is a scientific reality that our employment law has not yet caught up with. Until it does, my job is to make sure every patient I certify understands exactly where they stand and has the best possible foundation to protect both their health and their livelihood.
If you are a Massachusetts medical cannabis patient or considering certification in 2026, the most careful thing you can do is treat your employment situation as a clinical variable—not an afterthought. Know your employer's drug testing policy. Know whether your role is federally regulated or safety-sensitive. Keep your MassCIP registration current and your physician documentation thorough. The law in Massachusetts is genuinely on your side in many circumstances, but it requires you to be an informed, documented, and proactive participant in your own protection. Your certifying physician should be a partner in that process from day one.
Massachusetts THC Drug Testing and Employment Rights Through Eight Critical Lenses (2026)
Patients, employment attorneys, clinicians, regulators, and skeptics each evaluate cannabis workplace protections differently. These eight perspectives examine the evidence, the law, and the lived reality from every angle.
Patient Takeaway
If you are a registered Massachusetts medical cannabis patient and you test positive for THC at work, you have real legal rights under the Barbuto ruling—but those rights are not automatic or universal. Your employer must generally engage in an accommodation conversation before terminating you, and firing you solely for off-duty, medically supervised cannabis use may constitute disability discrimination under state law. However, if you drive commercially, work for a federal contractor, or hold a safety-sensitive role, those protections may not apply to you at all. Know your specific situation before you assume you are covered.
The tax exemption benefit of your medical card—saving 17% to 20% on every dispensary purchase—is real and immediate. The employment protection is real but conditional. Both are worth having, and neither replaces the need for an informed conversation with your certifying physician about your specific workplace context.
Clinician's Perspective
From a clinical standpoint, the employment risk associated with THC drug testing is a genuine therapeutic barrier that affects treatment adherence, dosing decisions, and patient wellbeing. Patients who fear job loss often under-dose, avoid daytime use even when clinically indicated, or select delivery methods based on detection-window anxiety rather than therapeutic efficacy. This is a clinically meaningful distortion of care that physicians must address directly.
The pharmacokinetics of THC metabolite clearance are well-characterized and should inform clinical guidance. A patient who uses a low-dose oral tincture three evenings per week will have a very different urine detection profile than a daily high-dose flower consumer—and that difference matters enormously in employment contexts. Personalized dosing guidance that accounts for both therapeutic goals and detection-window realities is a core component of responsible cannabis medicine.
Clinicians certifying patients for medical cannabis in Massachusetts should routinely document the patient's qualifying condition, the clinical rationale for cannabis therapy, and any discussion of employment risk. This documentation serves both the patient's legal interests and the physician's professional accountability. It is not optional—it is standard of care.
A Skeptical Read
The Barbuto ruling is real, but its practical enforceability for the average Massachusetts worker is limited by the cost and complexity of employment discrimination litigation. Most patients who are terminated after a positive THC test do not have the resources to file an MCAD complaint, retain an employment attorney, and pursue a case through the administrative and judicial process. The legal protection exists on paper more robustly than it exists in practice for workers without financial resources or union representation.
There is also a legitimate concern that some cannabis certification services overemphasize employment protections as a selling point without adequately communicating the significant exceptions and limitations. Patients deserve complete information, not reassurance that serves commercial interests.
Regulatory & Legal Analysis
The Massachusetts Cannabis Control Commission's regulatory framework under 935 CMR 501.000 governs patient registration and dispensary access but is largely silent on employment protections—those flow from M.G.L. c. 151B and the Barbuto SJC precedent, not from cannabis-specific regulation. This regulatory gap means that the CCC has no enforcement mechanism for employment discrimination against patients, leaving patients entirely dependent on the MCAD and civil courts for redress.
The interaction between state accommodation obligations and federal Drug-Free Workplace Act requirements creates a genuine regulatory incoherence that neither the CCC nor the Massachusetts Attorney General has fully resolved. Employers with mixed federal and state contracts face conflicting legal obligations, and the guidance available to them is inadequate. This ambiguity ultimately falls on patients, who bear the risk of an unresolved policy conflict they did not create.
The absence of validated, impairment-based THC testing technology in 2026 is a regulatory failure with direct patient consequences. The Massachusetts legislature has not acted to require impairment-based standards for workplace cannabis testing, leaving the metabolite-detection model—which bears no relationship to actual impairment—as the operative standard. Several other states have begun exploring impairment-based testing legislation; Massachusetts has not yet followed.
Equity dimensions of this issue deserve explicit attention. Workers in lower-wage, higher-turnover industries—food service, retail, warehousing, construction—are more likely to face routine drug testing and less likely to have the legal resources to enforce their Barbuto rights. The employment protection framework, as currently structured, provides the most robust protection to workers who need it least.
Comparative State & Historical Context
Massachusetts legalized medical cannabis via Ballot Question 3 in 2012, but the original statute contained no explicit employment protections. The Barbuto ruling in 2017 was a judicial innovation—the SJC extended existing disability discrimination law to cover medical cannabis patients in a way the legislature had not explicitly mandated. This judicial path to protection is more fragile than a statutory right and could theoretically be narrowed by future court decisions or legislative action, though neither appears imminent in 2026.
Compared to other states, Massachusetts sits in the middle tier of employment protection strength. New Jersey, New York, and Connecticut have enacted explicit statutory employment protections for medical cannabis patients that go beyond what Barbuto provides. States like Texas, Florida, and Georgia offer no comparable protection. Federal rescheduling, if finalized, could eventually create a more uniform national baseline—but that outcome remains speculative in 2026.
Dispensary Realities & Employment-Conscious Product Selection
For patients navigating employment drug testing risk, product selection at the dispensary is not just a therapeutic decision—it is a strategic one. Oral formulations (tinctures, capsules, edibles) produce more predictable and quantifiable dosing than inhalation, which matters when you are trying to manage your metabolite clearance timeline. Low-dose, high-CBD formulations minimize total THC metabolite load while still providing therapeutic benefit for many conditions.
The 17% to 20% tax exemption available to registered medical patients makes the financial case for maintaining your card unambiguous—but the medical dispensary menu also offers products not available in the adult-use market, including higher-dose therapeutic formulations and products specifically designed for clinical use. Ask your dispensary's patient care specialist about products with documented batch testing and consistent cannabinoid profiles; variability in potency is the enemy of predictable metabolite clearance.
Timing matters. Patients who consume cannabis exclusively in the evening, use oral rather than inhaled formulations, and maintain consistent low-to-moderate doses will generally have shorter and more predictable detection windows than those who use high-potency concentrates throughout the day. This is not a guarantee—individual metabolism varies significantly—but it is a clinically informed harm-reduction strategy that your certifying physician can help you personalize.
Federal Rescheduling, Impairment Testing, and the Road Ahead
The most consequential near-term development for Massachusetts cannabis employment rights is not a state legislative change—it is federal rescheduling. If the DEA finalizes Schedule III classification for cannabis, the legal basis for treating a positive THC test as equivalent to heroin use in federal employment contexts weakens substantially. Employers holding federal contracts would need to revisit their drug-free workplace policies, and the EEOC may issue updated guidance on cannabis accommodation obligations. Simultaneously, the development of validated, point-of-care impairment testing technology—oral fluid tests that detect recent THC exposure rather than weeks-old metabolites—could fundamentally transform the fairness of workplace cannabis testing. Several technology companies are in late-stage clinical validation of such devices in 2026, and their eventual adoption would represent the single most important practical improvement for medical cannabis patients in employment contexts. Until both of those developments materialize, Massachusetts patients must navigate the current framework with clear eyes and good documentation.
Common Myths & Dangerous Misconceptions
The most dangerous myth circulating in Massachusetts cannabis communities is that a medical card automatically protects you from any employment consequence of a positive THC test. It does not. The Barbuto ruling creates an obligation for employers to engage in an accommodation process—it does not prohibit drug testing, does not override federal law, and does not protect employees in safety-sensitive or federally regulated roles. Patients who believe their card is a blanket shield have been dangerously misinformed, often by sources with commercial interests in minimizing the complexity of this issue.
A second common misconception is that testing positive for THC proves you were impaired at work. It does not—and this distinction is legally and scientifically important. THC-COOH, the metabolite detected in standard urine tests, is pharmacologically inactive and provides no information about when cannabis was consumed or whether any impairment existed at the time of testing. Patients who understand this distinction are better equipped to advocate for themselves in accommodation conversations and, if necessary, in legal proceedings. Your certifying physician can provide documentation supporting this scientific reality.
💬 Join the Conversation
Have questions about qualifying for a medical marijuana card in Massachusetts? Ask Dr. Caplan →
Want to connect with other patients and discuss local dispensary options? Join the CED Clinic patient community forum →
A comprehensive breakdown of statutory and debilitating conditions under CCC regulations 935 CMR 501.
Explore guideHow CB1 and 5-HT1A serotonin receptor mechanisms govern anxiety modulation in the brain.
Explore scienceA candid physician examination of where cannabis excels, where it struggles, and how to dose safely.
Read analysisFrequently Asked Questions
Does the Barbuto ruling protect all Massachusetts employees with a medical cannabis card in 2026?
No. The Barbuto ruling under M.G.L. c. 151B requires most Massachusetts employers to engage in a reasonable accommodation process before terminating a registered medical cannabis patient solely for a positive THC test. However, it does not protect federal contractors, DOT-regulated employees (CDL drivers, pilots, railroad workers), or employees in roles where impairment creates direct safety risk. In 2026, with cannabis still pending full federal rescheduling, these exceptions remain fully operative and affect a substantial portion of the Massachusetts workforce.